You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 64 No. 2, February 2007 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Article
 This Article
 •Full text
 •PDF
 •Correction
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (3)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Cardiovascular System
 •Cardiovascular Disease/ Myocardial Infarction
 •Psychiatry, Other
 •Alert me on articles by topic

Relative Risk of Cardiovascular and Cancer Mortality in People With Severe Mental Illness From the United Kingdom's General Practice Research Database

David P. J. Osborn, PhD; Gus Levy, MSc; Irwin Nazareth, PhD; Irene Petersen, PhD; Amir Islam, MBA; Michael B. King, PhD

Arch Gen Psychiatry. 2007;64(2):242-249.

Context  People with severe mental illness (SMI) appear to have an elevated risk of death from cardiovascular disease, but results regarding cancer mortality are conflicting.

Objective  To estimate this excess mortality and the contribution of antipsychotic medication, smoking, and social deprivation.

Design  Retrospective cohort study.

Setting  United Kingdom's General Practice Research Database.

Patients  Two cohorts were compared: people with SMI diagnoses and people without such diagnoses.

Main Outcome Measure  Mortality rates for coronary heart disease (CHD), stroke, and the 7 most common cancers in the United Kingdom.

Results  A total of 46 136 people with SMI and 300 426 without SMI were selected for the study. Hazard ratios (HRs) for CHD mortality in people with SMI compared with controls were 3.22 (95% confidence interval [CI], 1.99-5.21) for people 18 through 49 years old, 1.86 (95% CI, 1.63-2.12) for those 50 through 75 years old, and 1.05 (95% CI, 0.92-1.19) for those older than 75 years. For stroke deaths, the HRs were 2.53 (95% CI, 0.99-6.47) for those younger than 50 years, 1.89 (95% CI, 1.50-2.38) for those 50 through 75 years old, and 1.34 (95% CI, 1.17-1.54) for those older than 75 years. The only significant result for cancer deaths was an unadjusted HR for respiratory tumors of 1.32 (95% CI, 1.04-1.68) for those 50 to 75 years old, which lost statistical significance after controlling for smoking and social deprivation. Increased HRs for CHD mortality occurred irrespective of sex, SMI diagnosis, or prescription of antipsychotic medication during follow-up. However, a higher prescribed dose of antipsychotics predicted greater risk of mortality from CHD and stroke.

Conclusions  This large community sample demonstrates that people with SMI have an increased risk of death from CHD and stroke that is not wholly explained by antipsychotic medication, smoking, or social deprivation scores. Rates of nonrespiratory cancer mortality were not raised. Further research is required concerning prevention of this mortality, including cardiovascular risk assessment, monitoring of antipsychotic medication, and attention to diet and exercise.


Author Affiliations: Department of Mental Health Sciences (Drs Osborn and King and Mr Levy) and Department of Primary Care and Population Sciences (Drs Nazareth and Petersen and Mr Islam), Royal Free and University College Medical School, London, England.



THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Antecedents and Sequelae of Sudden Parental Death in Offspring and Surviving Caregivers
Melhem et al.
Arch Pediatr Adolesc Med 2008;162:403-410.
ABSTRACT | FULL TEXT  

The emerging physical health challenges of antipsychotic associated hyperprolactinaemia in patients with serious mental illness
Dursun et al.
J Psychopharmacol 2008;22:3-5.
 

The evolution of hyperprolactinaemia as an entity in psychiatric patients
Kohen and Wildgust
J Psychopharmacol 2008;22:6-11.
ABSTRACT  

Antipsychotics and hyperprolactinaemia: Clinical recommendations
Peveler et al.
J Psychopharmacol 2008;22:98-103.
ABSTRACT  

Schizophrenia Host Vulnerability and Risk of Metabolic Disturbances During Treatment with Antipsychotics
Buckley et al.
Focus 2008;6:172-179.
ABSTRACT | FULL TEXT  

ANOTHER EXAMPLE OF AN ILLICIT CIGARETTE MARKET: A STUDY OF PSYCHIATRIC PATIENTS IN TORONTO, ONTARIO
Callaghan et al.
Am. J. Public Health 2008;98:4-5.
FULL TEXT  

Psychosocial Interventions and Successful Aging: New Paradigms for Improving Outcome for Older Schizophrenia Patients?
Vahia and Cohen
AJGP 2007;15:987-990.
FULL TEXT  

Metabolic disease and cardiovascular risk in people treated with antipsychotics in the community
Mackin et al.
Br. J. Psychiatry 2007;191:23-29.
ABSTRACT | FULL TEXT  

Serious Medical and Psychiatric Illnesses: How Often Are They Comorbid?
JWatch Psychiatry 2007;2007:4-4.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2007 American Medical Association. All Rights Reserved.